PTEN and prostate cancer: PI3K/Akt increases the stability of nuclear ß-catenin by phosphorylation and inactivation of the downstream substrate, GSK3ß, in prostate cancer cells, and PTEN deletion can augment PI3K/AKT action and increase cellular ß-catenin [10].